DETAILED ACTION
Status of the Claims
1. Claims 41-62 are pending.
Claim Objections
2. Claim 58 objected to because of the following informalities: Claim 58 recites compound of formula (II). There is no formula (II) listed in claim. Appropriate correction is required.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 46, 48 and 57 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Claim 46 recites the limitation "the surface" in line 3. It is unclear if “the surface” is polymeric surface or a different surface.
Claim 48 recites the limitation "the surface" in line 3. It is unclear if “the surface” is polymeric surface or a different surface.
Claim 57 recites the limitation "the surface" in line 3. It is unclear if “the surface” is polymeric surface or a different surface.
Allowable Subject Matter
Claims 41-62 are allowed.
The following is a statement of reasons for the indication of allowable subject matter: cited prior art, Andree et al. teach a device (biosensor; see page 218) comprising a doxycycline derivative, said doxycycline derivative immobilized on sensor chip surface; see Fig 1) for the detection of tetracycline. Andree et al. do not teach device comprising doxycycline derivative of formula (I) capable of binding to neurotoxic amyloid-type protein aggregates for detecting neurotoxic amyloid-type protein aggregates.
Cited prior art, Medina et al. teach doxycycline specifically bind to tau microtuble binding domain to prevent tau amyloid aggregation and interaction is measured with fluorescence emission (see section Real Time quaking induced conversion). Medina et al. also do not teach doxycycline derivative of formula (I) capable of binding to neurotoxic amyloid-type protein aggregates.
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to GURPREET KAUR whose telephone number is (571)270-7895. The examiner can normally be reached M-F 9:30-6.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Curtis Mayes can be reached at 571-272-1234. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/GURPREET KAUR/
Primary Examiner
Art Unit 1759
Prosecution Insights